Search clinical trials for: Repatha (evolocumab); Praluent (alirocumab)

Total 131 results

Second Xiangya Hospital of Central South University

Not yet recruiting

PCSK9 Inhibitor on ACS Patients With Multivessel Disease and Relatively Low LDL-C Level in Chinese Population

Acute Coronary Syndrome
LIB Therapeutics LLC

Completed

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients (LIBerate-H2H)

Cardiovascular Diseases | Hypercholesterolemia

United States
Federico II University

Recruiting

Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy (AT-TARGET-IT)

Hypercholesterolemia

Italy
Westside Medical Associates of Los Angeles
Regeneron Pharmaceuticals; University of Washington

Unknown

Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab

Atherosclerosis | Hyperlipidemia

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

Hypercholesterolemia

United States, Bulgaria, Chile, Estonia, Japan, Mexico, Russian Federation, South Africa, Ukraine
University of Virginia
Northwestern University

Completed

A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease

Peripheral Arterial Disease

United States
Regeneron Pharmaceuticals
Sanofi

Terminated

Long Term Safety Study of PRALUENT

Heterozygous Familial Hypercholesterolemia | Non-familial Hypercholesterolemia

United States, Bulgaria, Estonia, Russian Federation, South Africa, Ukraine
Washington University School of Medicine

Completed

Alirocumab and Reverse Cholesterol Transport

Atherosclerosis | Coronary Heart Disease

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy (ODYSSEY ESCAPE)

Heterozygous Familial Hypercholesterolemia

United States, Germany
Regeneron Pharmaceuticals
Sanofi

Terminated

Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study

Hypercholesterolemia

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (ODYSSEY HoFH)

Homozygous Familial Hypercholesterolemia

United States, South Africa, Canada, Greece, Japan, Ukraine, Austria, Czechia, France, Germany, Italy, Taiwan, Turkey
Regeneron Pharmaceuticals
Sanofi

Completed

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

Hypercholesterolemia

France, United States
University of Utah
Regeneron Pharmaceuticals

Terminated

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis (PINNACLE)

Stroke | Intracranial Atherosclerosis | Intraplaque Hemorrhage

United States
Virginia Commonwealth University
Sanofi; Regeneron Pharmaceuticals

Completed

Alirocumab in Patients With Acute Myocardial Infarction

Myocardial Infarction | Hypercholesterolemia

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol

Hypercholesterolemia

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Hypercholesterolemia | Heterozygous Familial Hypercholesterolemia

United States, Canada
Wolfson Medical Center
Sanofi; Assaf-Harofeh Medical Center

Unknown

Treatment of Severe Infection With Antihyperlipidemia Drug

Sepsis | Septic Shock

Israel
Radboud University Medical Center
Amgen

Recruiting

Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody (FITTER)

Coronary Artery Disease | Atherosclerosis of Coronary Artery

Netherlands
Sanofi
Regeneron Pharmaceuticals

Completed

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Atherosclerotic Cardiovascular Disease

China, Hong Kong, Austria, Bulgaria, Norway, Peru, France, Japan, Spain, Lithuania, Philippines, Israel, Belgium, Croatia, Poland, Hungary, Chile, Mexico, Latvia, Singapore, Switzerland, Colombia, Greece, Ukraine, Turkey, Finland, United States and more
Imperial College Healthcare NHS Trust
Imperial College London

Active, not recruiting

Effect of Evolocumab on Carotid Plaque Composition in Asymptomatic Carotid Artery Stenosis (EVOCAR-1) (EVOCAR-1)

Carotid Artery Stenosis

United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

Hypercholesterolemia

United States, Bulgaria, Canada, Norway, Israel, Slovakia, United Kingdom, Hungary
University of Salerno

Not yet recruiting

Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients (BESAFE)

Cardiovascular Diseases | Dyslipidemias | Lipid Metabolism Disorders | Statin Adverse Reaction
Rigshospitalet, Denmark

Withdrawn

Vascular Inflammation and Cholesterol Lowering Therapy

Lipid Lowering, Vascular Inflammation

Denmark
Amgen
Organization of Teratology Information Specialists (OTIS) Research Center...

Terminated

Evolocumab Pregnancy Exposure Registry

Hypercholesterolemia; ASCVD; Pregnancy
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

Hypercholesterolemia

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Open Label Study of Long Term Safety Evaluation of Alirocumab (ODYSSEY OLE)

Hypercholesterolemia

United States, Argentina, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Norway, Portugal, Romania, Russian Federation, South Africa, Spain, Sweden, United...
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan

Hypercholesterolemia

Korea, Republic of, Taiwan
Amgen

Completed

Safety and Tolerability of Repatha® (Evolocumab) in Indian Participants With Homozygous Familial Hypercholesterolemia (RAMAN)

Homozygous Familial Hypercholesterolemia HoFH

India
Gloria Vega
Regeneron Pharmaceuticals; Aventis Pharmaceuticals

Terminated

Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome

Nephrotic Syndrome

United States
Amgen

Terminated

Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia

Mixed Dyslipidemia | Primary Hypercholesterolemia

China
Baylor Research Institute
Regeneron Pharmaceuticals

Unknown

Alirocumab in Patients on a Stable Dialysis Regimen

Hemodialysis | Peritoneal Dialysis | Hypercholesterolemia | Atherosclerotic Disease

United States
LIB Therapeutics LLC

Completed

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

Homozygous Familial Hypercholesterolemia

United States, Israel, Norway, South Africa, Turkey, India
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

Hypercholesterolaemia

Netherlands, United States, Canada, Russian Federation, South Africa
Sanofi
Regeneron Pharmaceuticals

Completed

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

Hypercholesterolemia

Sweden, Germany, Russian Federation, Denmark, Israel, South Africa, Spain, Hungary, United States, Colombia, Czech Republic, Argentina, Belgium, Bulgaria, Canada, Chile, Finland, France, Italy, Mexico, Netherlands, Norway, Poland, Por... and more
University Hospital, Grenoble

Recruiting

Impact of PCSK9 Inhibitors on Coronary Microvascular Dysfunction in Patients With Atherosclerotic Cardiovascular Disease Proved by Myocardial Ischemia and Needing Coronarography (MICROPROTECT)

Atherosclerotic Cardiovascular Disease

France
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (ODYSSEY FH I)

Hypercholesterolemia

United States, Austria, Canada, Czech Republic, Denmark, France, Israel, Netherlands, Norway, Russian Federation, South Africa, Spain, Sweden, United Kingdom
UMC Utrecht
Erasmus Medical Center; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaborators

Unknown

Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia (EVOLVE-FD)

Hyperlipoproteinemia Type III | Familial Dysbetalipoproteinemia
Minneapolis Heart Institute Foundation
Regeneron Pharmaceuticals

Terminated

The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial (ASAP-SVG)

Saphenous Vein Graft Atherosclerosis

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

Hypercholesterolemia

United States, Australia, Belgium, Canada, Denmark, Netherlands, New Zealand, Spain
Amgen

Completed

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

Mixed Dyslipidemia | Primary Hypercholesterolemia

United States, Canada
Foundation IRCCS San Matteo Hospital
Fondazione Poliambulanza Istituto Ospedaliero; Azienda Ospedaliera Ordine Mauriziano... and other collaborators

Withdrawn

Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction (ExOTIC)

ST-elevation Myocardial Infarction

Italy
Amgen

Completed

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Mixed Dyslipidemia | Primary Hypercholesterolemia

United States, Canada
University of California, Los Angeles
Amgen

Terminated

Reducing Intracranial atheroSclErosis With Repatha (RISER)

Ischemic Stroke

United States
Johns Hopkins University
American Heart Association

Completed

Effect of Evolocumab on Coronary Endothelial Function (EVOLVE)

Coronary Artery Disease | Human Immunodeficiency Virus

United States
Hamad Medical Corporation

Not yet recruiting

The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients

Dyslipidemias | STEMI
Amgen

Completed

Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Hypercholesterolemia

Canada, Netherlands, Spain, Belgium, United States, Russian Federation, Czechia, Mexico, Korea, Republic of, Australia, United Kingdom, Argentina, Israel, France, Hungary, Germany, Greece, Poland, Switzerland, Italy, Brazil, Sweden, Norwa... and more
Stanford University
National Heart, Lung, and Blood Institute (NHLBI)

Enrolling by invitation

PCSK9 Inhibition After Heart Transplantation

Vasculopathy

United States
Fundació Institut Germans Trias i Pujol

Completed

EVOlocumab in Stable Heart Failure With Reduced Ejection Fraction of Ischemic Etiology: EVO-HF Pilot (EVO-HF)

Heart Failure With Reduced Ejection Fraction

Spain
Columbia University
Amgen

Terminated

Impact of LDL-cholesterol Lowering on Platelet Activation

Familial Hypercholesterolemia

United States
Amgen

Completed

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia (BANTING)

Type 2 Diabetes | Hypercholesterolemia | Mixed Dyslipidemia

United States, Italy, Belgium, Spain, Canada, Poland, Mexico

Search clinical trials for: Repatha (evolocumab); Praluent (alirocumab)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations